Better Health. Better Life.

M Pharmaceutical Closes On Chelatexx, Llc Acquisition

VANCOUVER, B.C., CANADA (July 15, 2016) - M Pharmaceutical, Inc. (CSE:MQ, OTCQB: MPHMF, FWB:T3F2 ), (the "Company" or “M Pharma”), has closed on its previously announced (April 6, 2016) agreement to acquire assets from Chelatexx, LLC related to a reformulated version of orlistat (product “C-103”).  The addition of C-103 provides a novel weight loss pharmaceutical product to the M Pharma pipeline. 

The Company paid an up-front cash payment of US$ 200,000, has issued 10 million common shares at a deemed price of $0.10 per share, and will pay a low single-digit royalty on net sales. 10% of the common shares issued will be subject to trading restrictions until November 8, 2016.  The balance of the common shares issued are subject to an escrow agreement that will have them released over the 3 years from the date of closing. 

Brian Keane, president of the Company, remarked “We are pleased that this transaction has now closed. Our next step is to finalize a development plan to move both this product and our Trimeo project into clinical trials and regulatory approvals. We see both these products providing much needed solutions to the current obesity problem.”

Gary Thompson, president of Chelatexx LLC, said “We are very excited to partner with a company so passionate about delivering weight loss solutions to a global market of almost 2 billion adults. Worldwide obesity has doubled since 1980 and now effects 41 million children under the age of 5. Using our patented Chelatexx technology, M-Pharma will be able to launch a reformulated Orlistat into a global market estimated to reach $7.8 billion by 2021.”

Background information on Orlistat

Orlistat is currently marketed in prescription strength by Roche Laboratories, Inc. (Xenical® 120mg capsules) and in over-the-counter strength by GlaxoSmithKline Consumer Healthcare (alli® 60mg capsules).  Orlistat has proven safe and effective in numerous clinical trials and remains the only FDA-approved weight management drug for a pediatric population (adolescents 12 years and older).  Orlistat does not affect the central nervous system and it is not systemically absorbed, as compared to other approved weight management drugs. 

Recent sales of orlistat have declined from its peak due to uncomfortable and well-publicized side effects of the product.  The development goal of the C-103 reformulation is to maintain the proven efficacy of orlistat while minimizing or eliminating the undesirable side effects.  Chelatexx, LLC holds issued U.S. patents covering C-103 technology until 2030.  The U.S. Food and Drug Administration has confirmed in writing that C-103 is eligible for 505(b)(2) approval in the U.S., under which the FDA is permitted to rely, for approval of the new drug, on data not developed by the applicant - such as published literature or the FDA's finding of safety and/or effectiveness of a previously approved drug product.  The Company cautions that there is no guarantee that C-103 will achieve its development goals and that there are no guarantees that C-103 will be approved by any health regulatory agency.

About M Pharmaceutical Inc.

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management.  In addition to the intended acquisition of C-103 from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights. 

M Pharmaceutical trades on the Canadian Securities Exchange (CSE) under the ticker symbol “MQ” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”  

For more information, contact:
Investor Relations\
Phone: +1 604 428 0511 


/s/ “Brain Keane, BSc”
Interim President and CEO

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the its biomedical technologies.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on and the Company’s filings to the CSE at  Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Drug Treatment Portfolio

Obesity, Weight Management Treatment

C-103 is a novel reformulation of orlistat, patented until 2030 in the U.S.  Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter).  Proven safe and effective in over 100 clinical trials, orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007.  The C-103 reformulation addresses adverse events reported by over 90% of orlistat users. These adverse events have led to the decline in Orlistat sales to approximately $200 million in recent years. 

C-103 is intended to maintain the efficacy of orlistat while minimizing its socially unacceptable adverse events. Unlike other weight loss drugs:

  • Orlistat is not an amphetamine
  • Orlistat does not affect the central nervous system
  • Orlistat is not systemically absorbed
  • Orlistat is the only FDA-approved OTC weight loss drug because of its safety
  • Orlistat is the only FDA-approved weight loss drug for adolescent patients (age 12-18)

Infertility Treatment

ToConceive is an innovative new infertility treatment that offers hope and assistance to the millions of couples worldwide struggling to start a family. Our product is an easy to use topical gel that helps to balance the pH of the vagina and is clinically proven to increases a women’s natural production of transudate (sexual lubrication). This increase in natural transudate is required for successful “Sperm Capacitation” to occur. Without the process of Sperm Capacitation, the sperm would not have the ability to travel the required distance to the ovum or have the appropriate chemical makeup for successful conception to occur.

ToConceive is a women’s health treatment supported by a FDA 510K clearance and is protected by four USPTO patents. ToConceive’s proven ability to increase a woman’s natural production of transudate results in significantly higher success rates for couples trying to conceive, without the added expense, or stress, associated with assisted reproduction treatments.